abstract |
A combination comprising an anti-PD-1 antibody selected from Nivolumab, Pembrolizumab, or Pidilizumab, and LCL161, for use in a method of treating a cancer or hematopoiesis disorder in a subject, wherein LCL161 is (S) -N - ((S) -1-cyclohexyl-2 - ((S) -2- (4- (4-fluorobenzoyl) thiazol-2-yl) pyrrolidin-1-yl) -2-oxoethyl) -2- (methylamino) propanamide or a pharmaceutically acceptable salt thereof. |